Table 1 |
||||||
|
Pharmacogenomics information on the top ten selling drugs in the world |
||||||
|
Generic name |
Therapeutic class |
Indications |
Genetic influence? |
Drug-induced phenotype |
Type of studies |
Genetic variant |
|
|
||||||
|
Atorvastatin |
Statins |
Dyslipidemia |
Yes |
Myopathy |
GWAS and candidate gene |
SLCO1B1 (drug transporter) |
|
Clopidogrel |
Anti-platelet agent |
Atherothombosis |
Yes |
Resistance to treatment |
GWAS and candidate gene |
CYP2C19 (hepatic enzyme) |
|
Esomeprazole |
Proton pump inhibitor |
Gastric ulcer |
Yes |
Drug efficacy |
Candidate gene |
CYP2C19 (hepatic enzyme) |
|
Fluticasone/Salmeterol |
Bronchodilator |
Asthma |
Possible |
Drug efficacy |
Candidate gene |
Beta-2 adrenoreceptor |
|
Etanercept |
TNF antagonist |
Rheumatoid arthritis |
Possible |
Drug efficacy |
GWAS and candidate gene |
MAFB |
|
Olanzapine |
Psychotropes |
Mental disorders |
Yes |
Drug efficacy |
GWAS and candidate gene |
ANKS1B; CNTNAP5 |
|
Risperidone |
Psychotropes |
Mental disorders |
Yes |
Drug efficacy |
GWAS and candidate gene |
ANKS1B; CNTNAP5 |
|
Darbopoetin |
Erythropoetin |
Anemia |
? |
- |
- |
- |
|
Venlafaxin |
Anti-depressant |
Depression |
Possible |
Drug efficacy |
Candidate gene |
CYP2D6; dopamine/serotonin transporter |
|
Amlodipine |
Anti-hypertensive |
Hypertensive |
? |
Drug efficacy |
Candidate gene |
NOS1AP |
|
|
||||||
|
Hulot Genome Medicine 2010 2:13 doi:10.1186/gm134 |
||||||